Learn how Ab Initio partners with leaders to produce next generation GMP MDIs ready for the clinic

Written By PY

This article is taken from Pharmaceutical Manufacturing and Packing Sourcer May 2023, Inhalation Technology Supplement pages 35–38. © Samedan Ltd

 

Ab Initio is please to announce an article published in the May 2023 Special issue of PMPS, highlighting how a collaborative CRO team can help develop faster MDI products for clients; from formulation and packaging considerations through to GMP manufacturing for clinical trials.

The article, authored by OzUK, H&T Presspart and Ab Initio highlights current challenges of taking new and exisiting MDI molecules through to market in a rapidly evolving landscape that includes innovation in MDI design and the use of next generation propellants.You can read the full article at Pharmaceutical Manufacturing and Packing Sourcer May Special Issue on Inhalation Technology, in Association with Respiratory Drug Delivery Europe here or by clicking on the article image.

PY
Previous

Ab Initio Pharma receives APVMA GMP licence to manufacture veterinary products
Next

Ab Initio publishes article in Inhalation Magazine | Fast-tracking inhalation product development using in vitro tools